Tsuyoshi Ikeda

Dr. Tsuyoshi Ikeda

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2023 in Genes
Verified
Journal Article
Open access
PDF file
HMHirotsugu Miyoshi
Hirotsugu Miyoshi
SOSachiko Otsuki
Sachiko Otsuki
KMKeiko Mukaida
Keiko Mukaida
KKKenshiro Kido
Kenshiro Kido
ASAyako Sumii
Ayako Sumii
Yasuo TsutsumiYasuo Tsutsumi
Yasuo Tsutsumi
Remimazolam is a novel general anesthetic and its safety in patients with malignant hyperthermia (MH) is unknown. We used myotubes derived from the skeletal muscle of patients with MH to examine the response to ryanodine receptor 1 (RYR1) agonist and remimazolam in MH-susceptible patients. Patients underwent muscle biopsy for the Ca2+-induced Ca2+ release (CICR) rate test, a diagnostic tool for MH in Japan. Ten patients had myotubes obtained from skeletal muscle cultures, and the genes associated with malignant hyperthermia in these patients were analyzed. The EC50 of caffeine, cresol, and remimazolam to induce intracellular calcium concentration change were compared between myotubes from CICR-negative genetic test patients and myotubes from other patients. Eight of the ten were CICR-positive, five of whom had RYR1 causative gene mutations or variants. Two patients had CICR-negative genetic tests, and as expected had the highest EC50 (the concentration of a drug that gives a half-maximal response) in response to caffeine, 4CmC and remimazolam. Three patients had a positive CICR but no known variants in RYR1 or CACNA1S (voltage-gated calcium channel subunit alpha1S). Myotubes in these patients had significantly lower EC50s for all agents than myotubes in CICR-negative patients. When myotubes from a patient who was CICR-negative and had no gene variant were used as a control, myotubes from CICR-positive patients were more hyper-responsive than controls to all stimulants used. The EC50 for remimazolam was lowest for myotubes from CICR-positive, RYR1-mutant patients, at 206 µM (corresponding to 123 µg/mL). The concentration was more than 80-times higher than the clinical concentration. RYR1 gene variants in R4645Q and W5020G were shown to be causative gene mutations for MH. Intracellular calcium in myotubes from MH patients are elevated at high concentrations of remimazolam but not at clinically used concentrations of remimazolam. Remimazolam appears to be safe to use in patients with MH.

11 August 2025 in Genes
Verified
Journal Article
Open access
PDF file
HMHirotsugu Miyoshi
Hirotsugu Miyoshi
KMKeiko Mukaida
Keiko Mukaida
SOSachiko Otsuki
Sachiko Otsuki
KKKenshiro Kido
Kenshiro Kido
ASAyako Sumii
Ayako Sumii
Yasuo TsutsumiYasuo Tsutsumi
Yasuo Tsutsumi
Background: Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle triggered by certain anesthetic agents. While Ryanodine Receptor 1 (RYR1) and Calcium Voltage-Gated Channel Subunit Alpha1 S (CACNA1S) are well-established susceptibility genes, the complete genetic basis of MH remains unclear, particularly in Asian populations. Methods: We conducted gene panel testing targeting 24 calcium-related genes in 338 individuals from 247 Japanese families with suspected or confirmed MH. Variants were analyzed on a gene-by-gene basis, and their pathogenicity was assessed using in silico prediction tools. Additionally, patients were classified into subgroups based on the results of the calcium-induced calcium release (CICR) assay and the Clinical Grading Scale (CGS) score. Results: Candidate pathogenic variants were identified in 118 families (48.2%), including 73 (29.8%) in RYR1, 16 (6.5%) in CACNA1S, and 62 (25.3%) in other genes. Among CICR-positive families, RYR1 and CACNA1S variants were detected in 42.0% and 5.3% of cases, respectively. In individuals with high CGS scores (Ranks 5–6), RYR1 and CACNA1S variants were observed in 56.0% and 12.0%, respectively. Variants in other genes such as STAC3, CASQ1, ATP2A1, ASPH, HRC and TRPV1 were also detected. Conclusions: Our findings confirm the predominant role of RYR1 and CACNA1S in MH susceptibility in the Japanese population and highlight additional candidate genes that may contribute to the condition. Broader genetic screening and functional validation studies are warranted to further elucidate the polygenic nature of MH.

8 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TITsuyoshi Ikeda
Tsuyoshi Ikeda
HMHirotsugu Miyoshi
Hirotsugu Miyoshi
GXGuo-Qiang Xia
Guo-Qiang Xia
KKKenshiro Kido
Kenshiro Kido
ASAyako Sumii
Ayako Sumii
Yasuo TsutsumiYasuo Tsutsumi
Yasuo Tsutsumi
Background/Objectives: Airway management techniques, including mask ventilation and tracheal intubation, are vital across medical settings. However, these procedures can be challenging, especially when environmental conditions are less than ideal. This study explores how the height of the operating table affects the difficulty of anesthesia techniques involving mask ventilation and tracheal intubation. Methods: Twenty anesthesiologists participated in this study. We assessed the difficulty of procedures such as mask ventilation, Macintosh laryngoscopy, and video laryngoscopy using McGRATH and AWS, on a four-level scale. The operating table’s height was adjusted at four points: the operator’s umbilicus, the inferior margin of the 12th rib, the xiphoid process, and the nipple. Results: Mask ventilation was easiest at the operating table’s height aligned with the inferior margin of the 12th rib. Conversely, direct laryngoscopic exposure was perceived as easier at higher table heights, with nipple height being optimal. The McGRATH laryngoscopy showed consistent difficulty across table heights, whereas the AWS tended to be somewhat more difficult at greater heights. Conclusions: The optimal bed height for video laryngoscopy coincided with that for mask ventilation. Video laryngoscopy offers enhanced flexibility in optimal patient positioning compared to Macintosh laryngoscopy, contributing to its advantages in tracheal intubation procedures.

20 August 2026 in Genes
Verified
Journal Article
Open access
PDF file
HMHirotsugu Miyoshi
Hirotsugu Miyoshi
SOSachiko Otsuki
Sachiko Otsuki
KKKenshiro Kido
Kenshiro Kido
ASAyako Sumii
Ayako Sumii
TITsuyoshi Ikeda
Tsuyoshi Ikeda
Yasuo TsutsumiYasuo Tsutsumi
Yasuo Tsutsumi
Background/Objectives: Malignant hyperthermia (MH) is a life-threatening pharmacogenetic disorder of skeletal muscle primarily associated with pathogenic variants in RYR1; however, a substantial proportion of MH-susceptible individuals lack identifiable variants in known genes. This study aimed to identify novel genetic contributors in Ca2+-induced Ca2+ release (CICR)-positive patients without RYR1 variants and to evaluate their functional relevance. Methods: Among 29 CICR-positive individuals without pathogenic variants identified by gene panel testing, five patients underwent whole-exome sequencing (WES). In one family, heterozygous variants in ANO5 (p.Arg547Gln) and ORAI3 (p.Arg287Cys) were identified. To evaluate their functional significance, intracellular Ca2+ dynamics were analyzed in primary myotubes derived from Case 165, an affected individual carrying both variants, and compared with those from CICR-negative controls and CICR-positive patients harboring RYR1 variants. Results: Myotubes derived from Case 165 demonstrated enhanced sensitivity to caffeine and 4-chloro-m-cresol, elevated resting intracellular Ca2+ levels, and greater Ca2+ reduction under Ca2+-free conditions compared with CICR-negative controls, resembling the phenotype observed in the RYR1 variant group. In contrast, dantrolene-induced Ca2+ reduction was significantly greater only in the RYR1 variant group. Conclusions: These findings suggest that ANO5 and ORAI3 variants may contribute to abnormal Ca2+ regulation in MH-susceptible individuals without RYR1 mutations and highlight the importance of combining genomic analysis with functional validation to identify novel genetic contributors to MH susceptibility.

23 September 2026 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
TITsuyoshi Ikeda
Tsuyoshi Ikeda
KMKeiko Mukaida
Keiko Mukaida
KKKenshiro Kido
Kenshiro Kido
GXGuo-Qiang Xia
Guo-Qiang Xia
ITIshii Tomomi
Ishii Tomomi
HMHirotsugu Miyoshi
Hirotsugu Miyoshi
BACKGROUND: Although hyperthermia exacerbates the pathophysiology of malignant hyperthermia (MH), the response to hypothermia remains poorly understood. MH susceptible-swine studies suggested that hypothermia prevents MH, yet clinical cases occur during hypothermic cardiopulmonary bypass. This study aimed to elucidate whether hypothermia inhibits the MH trigger or merely decelerates the progression of the lethal metabolic cascade. METHODS: Pharmacological sensitivity of type 1 ryanodine receptor was evaluated in myotubes from heterozygous p.R2509C knock-in mice and wild-type (WT) mice by measuring the half-maximal effective concentration of caffeine at 30 °C and 40 °C. Intracellular calcium dynamics were also assessed during temperature changes. In vivo, anesthetized male and female mice were exposed to 2.5% sevoflurane at rectal temperatures of 34 °C or 36 °C. Survival time, heart rate, arterial blood gas analysis, and muscle ultrastructure were compared. RESULTS: Compared with WT myotubes, R2509C myotubes showed a leftward shift in the caffeine dose–response curve and a lower half-maximal effective concentration at both 30 °C (estimated treatment effects = 2.0 mM, 95% confidence interval [CI], 0.5–3.6 mM, P = .020) and 40 °C (estimated treatment effects = 2.1 mM, 95% CI, 0.5–3.7 mM, P = .029). Cooling myotubes from 36 °C to 34 °C significantly reduced relative intracellular Ca 2 + fluorescence in R2509C myotubes. In vivo, all mutant mice developed MH and went into cardiac arrest regardless of temperature. Survival time was significantly longer at 34 °C compared to 36 °C (mean difference = 45.0 minutes, 95% CI, 20.9–69.1 minutes, P = .002). Typical signs such as tachycardia were absent at 34 °C. Despite masked clinical signs, progressive hypercapnia, metabolic acidosis, hyperkalemia, and characteristic mitochondrial swelling occurred in hypothermia. CONCLUSIONS: Hypothermia decelerates the clinical progression of MH but does not prevent triggering or lethality in mouse models. The caffeine-hypersensitivity of R2509C myotubes was detectable even under the lower-temperature assay condition. Mitochondrial swelling was identified as an ultra-early pathological change, suggesting that muscle damage is not solely driven by thermal injury. Clinicians should be aware that hypothermia may mask tachycardia and body temperature elevation, leaving hypercapnia and acidosis as critical early indicators.

31 May 2026 in American Journal of Case Reports
Verified
Journal Article
Open access
YMYuki Murao
Yuki Murao
KMKeiko Mukaida
Keiko Mukaida
HKHiroshi Kondo
Hiroshi Kondo
YNYukiko Nao
Yukiko Nao
MUMasaya Ueki
Masaya Ueki
Yasuo TsutsumiYasuo Tsutsumi
Yasuo Tsutsumi
Anesthesia Management in a Patient With a History of Fulminant Malignant Hyperthermia and a Homozygous RYR1 p.Arg530His Variant Undergoing Laparoscopic Surgery: A Case Report - Article abstract #953046